INTRODUCTION
Platelet membrane glycoproteins have been implicated in von Willebrand factor-dependent ristocetininduced platelet aggregation (1) (2) (3) . Three major membrane glycoproteins with apparent mol wt of 155,000 (glycoprotein I), 135,000 (glycoprotein II), and 100,000 (glycoprotein III) are present on the surface of the human platelet (2, (4) (5) (6) . Recent studies suggest that glycoprotein II can be resolved further into two separate components Ila and Ilb (1) . Platelets from patients with Glanzmann's thrombasthenia have decreased amounts of glycoprotein Ilb (3, 7) . Platelets from patients with the Bernard-Soulier syndrome show decreased adhesion to rabbit aorta subendothelium, and fail to aggregate with the antibiotic ristocetin in the presence of plasma von Willebrand factor (8, 9) . Several recent studies have demonstrated an abnormality in the membrane glycoproteins of BernardSoulier platelets (1, 3) . These giant platelets contain diminished amounts of sialic acid, and have Dr. Jaffe is the recipient of an NIH Research Career De- velopment Award 1 K04 HL 00237 and a Career Scientist Award from the Irma T. Hirschl Trust. Received for publication 2 July 1976. decreased amounts and (or) molecularly altered forms of glycoproteins I-III (1, 3, 10) . Nurden and Caen's studies suggest that the major membrane lesion in the Bernard-Soulier syndrome involved a marked reduction in glycoprotein I (mol wt 155,000); references 3 and 10. This surface glycoprotein, which is high in sialic acid, may serve as a potential receptor for a component(s) of the subendothelium during the platelet's interaction with this structure (1, 2) . The possibility has also been raised that this 155,000 mol wt surface glycoprotein serves as a receptor for the plasma von Willebrand factor during aggregation induced by ristocetin (2, 11) . It has previously been demonstrated that chymotrypsin-treated normal platelets have decreased membrane glycoproteins and aggregate poorly in the presence of von Willebrand factor and ristocetin (1) . Similarly, trypsin-treated, formalin-fixed platelets do not bind von Willebrand factor and do not aggregate in the presence of plasma and ristocetin whereas nonenzyme-treated fixed cells do (12) .
These observations suggested that selective proteolytic digestion of platelets might allow analysis of the surface protein(s) which interact directly with the von Willebrand factor and/or ristocetin. For this purpose, antibodies were produced in rabbits to paraformaldehyde-fixed washed platelets. The antibodies were absorbed with chymotrypsin-treated, fixed platelets and studied for the ability to induce a Bernard-Soulier-like abnormality in normal platelets. The results suggest that antibodies with an apparent specificity for surface glycoprotein I block ristocetininduced aggregation of normal platelets.
METHODS
Formalin-fixed washed platelets. Platelet-rich plasma was prepared as previously described (13) . The platelets were separated from plasma and washed three times using the Ardlie buffer system (14 Antisera. Antisera to fixed washed platelets were produced in rabbits. 2 x 108 fixed washed platelets were washed twice in PBS, emulsified with an equal volume of complete Freunds' adjuvant, and injected into multiple intradermal sites on the rabbit's shaved back. The animals were reimnmnized with intradermal injections at 2 and 4 wk, and with an intramuscular injection (without adjuvant) at 2 mo. Antiserum was obtained 2 wk after the final injection.
The antisera were absorbed four times with chymotrypsintreated, fixed washed platelets; 1 ml of antiserum was incubated with 2 x 109 washed chymotrypsin-treated, fixed platelets for 1 h at 37°C and 2 h at 4°C. The absorbed antisera (anti-FWP (fixed washed platelets)) did not agglutinate the chymotrypsin-treated, fixed platelets in buffer but did agglutinate nonenzyme-treated, fixed washed platelets at dilutions of 1:10-1:20. The absorbed antisera were further absorbed for 1 h at 37°C with human factor VIII concentrate (5 U factor VIII/ml antisera) (Profilate, Abbott Laboratories, Diagnostics Div.). The absorbed antisera were absorbed once with 0.1 vol aluminum hydroxide gel (Accurate Chemical & Scientific Corp., Hicksville, N. Y.) and heated to 560C for 30 min to remove residual coagulation proteins. Anti-FWP had no inhibitory effect on VIII:AHF (antihemophilic factor, clotting activity) in human plasma as compared to nonimmune rabbit serum (15) . The inhibition of VIII:AHF in human plasma by anti-FWP was assayed after equal volumes of antibody and plasma were incubated for 2 h at 37°C. The mixture was assayed for VIII:AHF by a one-stage method using VIII:AHF-deficient plasma (16) . Commercial antifibrinogen, antialbumin, anti-IgG globulin, anti-IgM globulin, anti-a2-macroglobulin, anti-C3, and anti-factor VIII were obtained from Behring Diagnostics, American Hoechst Corp., Somerville, N. J. Antibody to platelet myosin was prepared by the method of Pollard et al. (17) and characterized as previously described (18) .
y-Globulin fractionts. y-Globulin fractions of the antisera were prepared as described by Kolb et al. (19) . The antiserum was dialyzed for 24 h at 4°C against 500 vol of sodium phosphate buiffer (0.01 M phosphate, pH 7). After removal of insoluble protein by centrifuigation at 3,000g for 30 min, the dialyzed sample was applied to a 1.5 x 28-cm TEAEcellulose column equilibrated with the dialysis buffer. The break-through protein was collected and concentrated by precipitation at 0°C with 50%o ammonium sulfate, then dissolved in and dialyzed against 0.15 M NaCl. F(ab')2 fragments were prepared by dialyzing the IgG fractions (10 mg/ml) against 0.1 M acetate, pH 4.5, overnight at 4°C, and digesting the protein for 7 h at 37°C with 0.4 mg pepsin (Worthington Biochemical Corp.) per 100 mg of IgG. The pepsin was then inactivated by raising the pH of the mixture to 7.5 using 1 M Tris buffer. The F(ab')2 fragments were separated from the Fc fragments by gel filtration oIn a Bio-gel A 0.5-in column (Bio-Rad Laboratories, Richmond, Calif.) using 0.05 M Tris, 0.01 M citrate, 0.154 M NaCl, pH 8.0 buffer. The F(ab')2 peak was concentrated by uiltrafiltration using a ProDiCon ultrafiltration apparatus (Bio-Molecular Dynamics, Beaverton, Oreg.), and reduced for 6 h at 37°C in 0.01 M cysteine. Sodium dodecyl sulfate (SDS)-gel electrophoresis of the Fab fragments in the unreduced state revealed a single mol wt species of 50,000 which moved with a mol wt of 25,000 after reduction with dithiothreitol.
SDS-gel electrophoretic analysis ofiodinated washed platelets. This was performed essentially as described by Jenkins et al. (1) . Washed human platelets were prepared as described above, except that the final wash was in 0.01 M Tris, 1 mM EDTA, pH 7.4. 1.2 mCi of 1251 (Amerslham!i/ Searle Corp.) was added to a stirred 1-ml suspension of 109 washed platelets in the Tris EDTA buffer followed by 10 ,ul 0.1 M sodium phosphate, pH 7.4, containing 30 ,ug lactoperoxidase (Calbiochem, San Diego, Calif., purified grade 100 IU/mg). Four 10-pul aliquots of freshly prepared hydrogen peroxide solution (1 mM in 0.154 M NaCI) were then added at 10-s intervals. 3 ml of the Tris EDTA buffer was then added and the platelets sedimented and washed in the same buffer. The final platelet pellet was resuspended in 0.4 ml water, 0.2 ml 10% SDS was added, and the pellet solubilized by boiling at 100°C for 5 min. Portions of the SDS-solubilized platelets were reduced immediately before electrophoresis by boiling for 3 min, with equal volumes of a mixture containing 2% 2-mercaptoethanol, 8 M urea, and 2% SDS in 0.02 M soditum phosphate buffer, pH 7.35. The samples were analyzed by SDS-polyacrylaimiide gel electrophoresis as described by Weber and Osborn (20) using 5% gels. Radioactivity labeling patterns were determined by slicing the gels and assaying the radioactivity of the individual fractions in a gamma spectrometer. Gel slices were 2.0 mm in thickness.
Immunoprecipitation studies of solubilized iodinated platelets. For these studies the iodinated platelets were washed and solubilized in Lubrol PX (Sigma Chemical Co.) as previously described (21) . 1 x 109 iodinated washed platelets were incubated for 18 h at 4°C in 0.5 ml PBS containing 0.1% Lubrol, 0.4 mM N-CBZ-a-L-glutamyl L-tyrosine, 250 Axg/ml soybean trypsin inhibitor (Worthington Biochemical Corp.), 0.5 mM phenyl methylsulfonyl fluoride, and Trasylol 100 U/ml (FBA Pharmaceuticals, New York). The soluble protein was separated from the residual insoluble material by ultracentrifugation at 100,000 g for 1 h at 4°C. Soluble human platelet membrane protein was prepared using Lubrol PX as previously described (21 
RESULTS
Inhibition of ristocetin-induced aggregtion by chymotrypsin treatment of fixed washed platelets. Ristocetin alone did not aggregate fixed washed platelets in buffer. In the presence of a small amount of plasma, marked aggregation occurred with the addition of ristocetin to a final concentration of 1 mg/ml (Fig. la) . Digestion of the fixed washed platelets with chymotrypsin abolished this aggregation (Fig. lb) .
Immunoinhibition of ristocetin-induced platelet aggregation. Nonprecipitating antibodies raised in rabbits to fixed washed platelets were absorbed extensively with chymotrypsin-treated, fixed washed platelets and human factor VIII concentrate. The absorbed intact antiserum did not agglutinate chymotrypsin-treated, fixed washed platelets but did agglutinate nonenzyme-treated, fixed washed platelets in buffer, and normal platelets in platelet-rich plasma. The absorbed antiserum had no inhibitory effect on the factor VIII procoagulant activity in normal plasma. Monovalent Fab fragments of the isolated y-globulin fraction of this antiserum were utilized to study the ristocetin reaction. Anti-FWP Fab fragments blocked ristocetin-induced aggregation of fixed washed platelets (Fig. 2a) . Control Fab fragments of antifibrinogen had no effect (Fig. 2b) . In addition, intact y-globulin preparations from the following antisera were noninhibitory: antialbumin, anti-C3, anti-a-2-macroglobulin, anti-IgM, anti-IgG, and antiplatelet myosin. Anti-factor VIII y-globulin-inhibited ristocetin-induced aggregation of the fixed washed plate- lets. This inhibition was abolished by absorption of the anti-factor VIII with human factor VIII concentrate. Anti-FWP Fab fragments completely abolished ristocetin-induced aggregation in platelet-rich plasma (Fig. 3a) . Antifibrinogen Fab fragments had no effect (Fig. 3b) .
Specificity of anti-FWP. Aggregation studies were performed to determine whether the inhibition by anti-FWP was specific for ristocetin-induced aggregation. Anti-FWP Fab fragments inhibited ristocetininduced platelet aggregation and serotonin release in platelet-rich plasma (Table I ). In contrast, the antibody fragments had no effect on the platelet aggregation or serotonin release in platelet-rich plasma induced by arachidonic acid, thrombin, collagen, (25) . Okumura and Jamieson (11) have isolated a platelet glycoprotein, glycocalicin, which blocks ristocetin-induced platelet aggregation presumably by competitive inhibition. These studies taken together suggest that surface glycoproteins are )R involved in ristocetin-induced platelet aggregation. Fig. 4a . This possibility that the lesion in this disorder is related to Lescribed (1, 22) (Fig. 4b) of the binds to fixed platelets in the presence of ristocetin ared to contain all (12) . We have previously suggested that ristocetin may ig. 4a though the alter platelet surface VIII:VWF so as to sterically -antibody immuno-reorient unavailable or masked sites (21) . The fact that bilized surface io-I using y-globulin hen goat anti-rabbit 1 electrophoresis of Fig. 4c) (26) suiggests that the mechlaniismii of action of ristocetin-may be related to its ability to convert the lhuiman VIII system to a more bovine form. One of the major differences between bovine and human f:actor VIII is in their carbohydrate cointent (27) . Sttudies on bovine factor VIII have indicated that the integrity of carbohydrate side chainis on the VIII molecule is necessary for subsequent aggregation responses (28, 29) . The importance of carbohydrate in this system has been strengthened by the recent demonstration that, in some patients with von Willebrand's disease, the VIII:VWF molecule differs from normal VIII:VWF in the carbohydrate portion (30) . Although ristocetin-induced aggregation is clearly a nonphysiological phenomenon, it has proven to be a useftil probe of the initial events of primary hemostasis.
Our studies were designed to analyze the protein(s) on the platelet surface, in addition to VIII:VWF, whiclh are necessary for the ristocetin-mediated aggregatioon respoinse. We uitilized, as immuniogens, paraformaldehyde-fixed platelets whichl serve as inert, metabolically inactive particles in this reaction (31) . The fact that fixed platelets aggregate in the presence of ristocetin and VIII:VWF is an arguiment for the surface localization on paraformaldehyde-fixed platelets of the platelet component involved in the response. Chymotrypsintreated normal platelets (1) as well as chymotrypsintreated, fixed platelets (Fig. 1) do not aggregate in the ristocetin system. It would appear logical from these observations that enzymatic degradation releases or destroys the surface protein necessary for the aggregation reaction. Antisera to fixed washed platelets were absorbed with chymotrypsin-treated, fixed washed platelets to obtain a reagent specific for those surface components involved in ristocetin aggregation. It was necessary to absorb the antisera with plasma factor VIII to nile out a direct anti-VIII:VWF effect. The fully absorbed antisera had no demonstrable anti-VIII:AHF (clotting) activity. Because platelets have a membrane Fc receptor, immunoinlhibition studies were performed with nonagglutinating Fab fragments (32) . The nonagglutinating monovalent Fab fragments blocked the ristocetin-induced aggregation of normal platelets and fixed washed platelets (Fig. 2) while bivalent intact anti-FWVP y-globulin aggltutinated normal platelets and fixed washed platelets. These observations arguie for a surface specificity of the antisera. The fact that anti-FWP Fab fraagmllents inhibited ristocetin-induced aggregation of normal platelets in plasma but had no effect on arachidonic acid, thrombin, collagen, or ADP-induced platelet aggregation indicated a significant degree of restricted membrane specificity (Table I) .
The double antibody immunoprecipitation sttudies demonstrate that anti-FWP reacted with a Ltubrolsolubilized radiolabeled surface component(s) of 155,000 mol wt. It shouild be noted that Ltubrol may not have soltubilized all of the membrane surface components. Thus it is possible that one or more other membrane constituents, not detectable by these techniques, also participate in the ristocetin-induced VIII:VWF platelet response. In sum, our results suggest that anti-FWP blocked a platelet membrane protein of the same molectular weight as the surface glycoprotein I which is deficient in Bernard-Soulier disease and which may interact with von Willebrand factor on the surface of the platelet. It is not possible from ouir studies to determine whether glycoprotein I on the platelet surface acts as a trie receptor for VIII:VWF or functions as one part of a larger macromolecular complex which leads to platelet aggregation in the presence of ristocetiin and von Willebrand factor by processes yet to be determined.
